Inflammasome Activation in Myocardial Ischemia/Reperfusion Injury

Myocardial ischaemia/reperfusion injury arises when the restoration of blood flow to the heart paradoxically exacerbates tissue damage through oxidative stress, calcium overload and immune activation. Central to this response is the assembly of inflammasome complexes, notably the NLRP3 inflammasome, which senses mitochondrial dysfunction and reactive oxygen species accumulation. Activation of caspase-1 within the inflammasome leads to maturation of interleukin-1β and interleukin-18 and triggers pyroptosis, a proinflammatory form of cell death. This cascade amplifies local inflammation, recruits neutrophils and monocytes, and propagates microvascular obstruction, ultimately impairing cardiac function. Increasingly, research has elucidated upstream regulators—such as mitochondrial proteins, ubiquitin ligases and pattern-recognition receptors—and demonstrated that targeted modulation of inflammasome activation can limit infarct size, preserve ventricular performance and offer translational promise in acute myocardial infarction.

Research from Nature Portfolio

Studies have delineated how metabolic stress induced by high fructose intake promotes CD36-mediated toll-like receptor 4/6–IRAK4/1 signalling, leading to NLRP3 inflammasome assembly in cardiomyocytes and fibroblasts. In experimental models, pharmacological agents with antioxidant properties—such as cinnamaldehyde and allopurinol—attenuate oxidative stress, disrupt CD36-dependent receptor activation and suppress downstream NLRP3 activation. These interventions reduce interleukin-1β release, dampen fibroblast Smad2/3 phosphorylation and mitigate myocardial inflammation and fibrosis. This work highlights a molecular link between lipid handling, innate immune recognition and inflammasome-driven remodelling, suggesting that inhibiting CD36-TLR signalling may represent a novel strategy to protect the post-ischaemic heart.

Inflammasome Activation in Myocardial Ischemia/Reperfusion Injury publication trend

The graph below shows the total number of articles in inflammasome activation in myocardial ischemia/reperfusion injury across all publications each year (not limited to Nature Index journals).

Technical terms

Inflammasome: a multiprotein complex that activates caspase-1 and orchestrates maturation of proinflammatory cytokines.
Pyroptosis: an inflammatory form of programmed cell death characterised by cell lysis and cytokine release.
NLRP3: a nucleotide-binding sensor protein that oligomerises in response to cellular stress to form the inflammasome.
Ischaemia/Reperfusion Injury: damage caused when blood flow returns to tissue after a period of oxygen deprivation, invoking oxidative and inflammatory responses.
Ubiquitination: a post-translational modification in which ubiquitin is attached to target proteins, often marking them for degradation.

References

1. Magnetic vagus nerve stimulation alleviates myocardial ischemia-reperfusion injury by the inhibition of pyroptosis through the M2AChR/OGDHL/ROS axis in rats. Journal of Nanobiotechnology (2023).
2. The E3 ubiquitin ligase MARCH2 protects against myocardial ischemia-reperfusion injury through inhibiting pyroptosis via negative regulation of PGAM5/MAVS/NLRP3 axis. Cell Discovery (2024).
3. NEDD4 ameliorates myocardial reperfusion injury by preventing macrophages pyroptosis. Cell Communication and Signaling (2023).
4. Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation. Scientific Reports (2016).